GlycoMimetics Inc (GLYC)
0.242
+0.03
(+11.78%)
USD |
NASDAQ |
Dec 24, 16:00
GlycoMimetics Cash from Operations (Quarterly): -7.994M for Sept. 30, 2024
Cash from Operations (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
Cash From Operations Definition
Cash flow from operations is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall operating activities of the company. A few examples of operating activities include change in receivables, change in inventories, and changes in current assets.
Cash from Operations (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Operations (Quarterly) Benchmarks
| Biomarin Pharmaceutical Inc | 221.48M |
| Arbutus Biopharma Corp | -20.74M |
| Revance Therapeutics Inc | -41.09M |
| FibroGen Inc | -8.376M |
| Cidara Therapeutics Inc | -36.70M |
Cash from Operations (Quarterly) Related Metrics
| Free Cash Flow | -35.02M |
| Free Cash Flow Per Share (Quarterly) | -0.124 |
| Free Cash Flow Yield | -224.5% |